Australia's industry body to review direction:
This article was originally published in Clinica
The Medical Industry Association of Australia (MIAA) is to develop a new strategic plan as part of an attempt to decide how it can best help its members meet and help shape the changing industrial environment. "Our industry is experiencing substantial change - and we need to develop an agreed view of just what [it] will look like five years out," said MIAA CEO Brian Vale. Mergers, takeovers, the decline in manufacturing and the rise of e-commerce are all contributing to the emerging environment, according to Mr Vale.
You may also be interested in...
Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.
The UK's Celleron has attracted a "blue chip suite of investors" to an Irish-domiciled spin-off based on the potential of Roche-developed emactuzumab for TGCT, a debilitating orphan disease that causes joint damage and has limited clinical options.
Topline results with AZD1222 have shown a lower efficacy rate than the Pfizer and Moderna vaccines, but a subgroup receiving a half-dose in their first injection showed a 90% efficacy result.